Summary
The effects of a single dose of alinidine (0.5 mg/kg i.v.), the N-allyl-derivative of clonidine, on heart rate and blood pressure were investigated in healthy volunteers and in patients with hyperkinetic heart syndrome, at rest and during bicycle exercise. In healthy volunteers plasma catecholamine levels were also determined. Alinidine did not change heart rate at rest in the healthy volunteers but it did significantly reduce exercise-induced tachycardia, whereas blood pressure and plasma catecholamine levels were not significantly affected by alinidine, either at rest or during exercise. In patients with hyperkinetic heart syndrome, alinidine reduced heart rate at rest and during exercise to a similar extent as propranolol (0.1 mg/kg i.v.). The blood pressure did not change with alinidine but it was significantly reduced by propranolol. The observation that an alinidine-induced reduction of heart rate occurs without a concomitant fall in blood pressure, and without a clonidine-like symphatho-inhibitory action, is in line with experimental findings suggesting a specific bradycardic action of alinidine under short-term conditions.
Similar content being viewed by others
References
Christensen NJ, Brandsborg O (1973) The relationship between plasma catecholamine concentration and pulse rate during exercise and standing. Eur J Clin Invest 3: 299–306
Da Prada M, Zürcher G (1976) Simultaneous radioenzymatic determination of plasma and tissue adrenaline, noradrenaline and dopamine within the femtomole range. Life Sci 19: 1161–1174
Haber E, Körner T, Page LB, Kliman B, Purnode A (1969) Application of a radioimmunoassay for angiotensin I to the physiologic measurement of plasma renin activity in normal human subjects. J Clin Endocrinol Metab 29: 1349–1355
Hansson BG, Hökfelt (1975) Long term treatment of moderate hypertension with penbutolol (Hoe 893 d). I. Effects on blood pressure, pulse rate, catecholamines in blood and urine, plasma renin activity and urinary aldosterone under basal conditions and following exercise. Eur J Clin Pharmacol 9: 9–19
Harron DWG, Riddell JG, Shanks RG (1981) Alinidine reduces heart-rate without blockade of beta-adrenoceptors. Lancet 1: 351–353
Kaspar W, Meinertz T, Treese N, Kerstin F, Pop T, Jähnchen E (1981) Clinical electrophysiological properties of N-allyl-clonidine (ST 567) in man. J Cardiovasc Pharmacol 3: 39–47
Kobinger W, Lillie C, Pichler L (1979a) N-allyl-derivative of clonidine, a substance with specific bradycardic action at a cardiac site. Naunyn-Schmiedebergs Arch Pharmacol 306: 255–262
Kobinger W, Lillie C, Pichler L (1979b) Cardiovascular action of N-allyl-clonidine (ST 567), a substance with specific bradycardic action. Eur J Pharmacol 58: 141–150
Lake CR, Ziegler MG, Kopin IJ (1976) Use of plasma norepinephrine for evaluation of sympathetic neuronal function in man. Life Sci 18: 1315–1326
Lillie C, Kobinger W, Pichler L (1979) ST 567, 2-N-allyl-N-(2,6-dichlorophenyl)-2-imidazoline, a specific bradycardic agent. Naunyn-Schmiedebergs Arch Pharmacol 307: R40
Metz SA, Halter JB, Porte D Jr, Robertson RP (1978) Suppression of plasma catecholamines and flushing by clonidine in man. J Clin Endocrinol Metab 46: 83–90
Reiterer W (1976) Evaluation of physical performance by rectangular-triangular bicycle ergometry and computer-assisted ergospirometry. Basic Res Cardiol 71: 482–487
Traunecker W, Walland A (1980) Haemodynamic and electrophysiologic actions of alinidine in the dog. Arch Int Pharmacodyn Ther 244: 58–72
Zimpfer M, Fitzal S, Semsroth M (1982) Relative roles of heart rate and ventricular stroke volume for the regulation of cardiac output during controlled hypotension with sodium nitroprusside in man. Eur J Clin Invest 12: 9–13
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stanek, B., Reiterer, W., Placheta, P. et al. Acute effects of alinidine on heart rate and blood pressure in healthy subjects and patients with hyperkinetic heart syndrome. Eur J Clin Pharmacol 24, 31–34 (1983). https://doi.org/10.1007/BF00613923
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613923